BehaveNet^®
Clinical Capsule™

Join Our Mailing List

For Email Newsletters you can trust

drug: buprenorphine

*

Clinical class	narcotic analgesic; replacement
Action	mu opioid partial agonist; kappa opioid antagonist
Chemical class	opioid, thebaine derivative, phenanthrene
CSA schedule	III, V
DEA number	9064
Routes of administration	parenteral, sublingual, transdermal
Associated with (substance-related)	disorders: disorders
Availability	prescription

Also:

U.S. Preparations:

Buprel™(DrugAbuse Sciences) in development
Buprenex (Reckitt Benckiser) FDA approved indications: relief of moderate to severe pain 12.29.1981
Norvex™ (Biotek) FDA approved indications: not approved
Probuphine™ (Titan) in development
Suboxone^® (combination with naloxone)

Dose:	2.0 mg. buprenorphine/0.5 mg. naloxone		8.0/mg. buprenorphine/2.0 mg. naloxone
Color:	orange		orange
Shape:	hexagonal		hexagonal
Type:	tablet		tablet
Imprint:	sword logo	"N2"	sword logo	"N8"

Subutex^® (Reckitt Benckiser) FDA approved indications: treatment of opiate dependence 10.8.2002

Dose:	2.0 mg.		8.0 mg.
Color:	white		white
Shape:	oval		oval
Type:	tablet		tablet
Imprint:	sword logo	"B2"	sword logo	"B8"

International Preparations:

Anorfin, Buprex, Burondal, Prefin, Temgesic^®
Temgesic^® nX (combination with naloxone)
Transtec^® (Napp)

Street Names:

bupe

Treatment Guidelines

Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. (SAMHSA)

Books and Other Media:
Follow the hypertext link to purchase items.

Cowan, Alan & Lewis, John W. (Editors) Buprenorphine - Combating Drug Abuse With a Unique Opioid Paperback 1995

Kings and Queen DVD (2004) Emmanuelle Devos, Mathieu Amalric, Catherine Deneuve

Stein, Michael The Addict: One Patient, One Doctor, One Year 2009

*Molecule graphic courtesy of Steve Chapman

http://www.behavenet.com/capsules
Search Capsules™ | Terms of Use | Request New Term
Capsules™ Copyright © 1997-2009 BehaveNet®